Andy Parker predicts StepPharma will move lymphoma trial into safety expansion cohort and make phase two decisions by end of 2026.
“So we will soon be going into safety expansion cohort. And at that point, we will establish what degree of efficacy we're seeing in a defined patient population, and that'll help us decide towards the end of this year where we're going from a phase two perspective.”
→ Read the source episode
Our resolution criterion
disputableStepPharma announces transition of lymphoma trial to safety expansion cohort and reports phase two advancement decision by 2026-12-31
More from Beyond Biotech
Stuart Medina predicts Bio Spain 2026 Talent Day will exceed the 125 job interviews arranged in the previous year
Per London predicts EVOX will generate initial clinical data from Huntington's trials in 2028-2029.
Per Lundin predicts EVOX's Huntington's gene editing therapy will be in routine clinical use within 10 years from 2026.
Narissa Kreyer predicts Alterna will demonstrate AP-003 establishes functional protein and impacts biomarkers/efficacy endpoints in humans within five years
Per London expresses hope that EVOX's Huntington's therapy will be routinely used clinically within 10 years (by 2036).
Laurent Levy predicts Nanobiotics will report randomized phase two lung cancer trial results before H1 2027
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.